X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aurobindo Pharma with Piramal Healthcare - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs PIRAMAL ENTERPRISES - Comparison Results

AUROBINDO PHARMA    Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA PIRAMAL ENTERPRISES AUROBINDO PHARMA/
PIRAMAL ENTERPRISES
 
P/E (TTM) x 14.2 36.4 39.1% View Chart
P/BV x 3.7 3.0 120.8% View Chart
Dividend Yield % 0.4 0.8 53.1%  

Financials

 AUROBINDO PHARMA   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-17
PIRAMAL ENTERPRISES
Mar-17
AUROBINDO PHARMA/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs8952,095 42.7%   
Low Rs6221,025 60.7%   
Sales per share (Unadj.) Rs254.6492.8 51.7%  
Earnings per share (Unadj.) Rs39.372.6 54.1%  
Cash flow per share (Unadj.) Rs46.694.7 49.2%  
Dividends per share (Unadj.) Rs2.5021.00 11.9%  
Dividend yield (eoy) %0.31.3 24.5%  
Book value per share (Unadj.) Rs160.0862.5 18.5%  
Shares outstanding (eoy) m585.88172.56 339.5%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.03.2 94.1%   
Avg P/E ratio x19.321.5 89.8%  
P/CF ratio (eoy) x16.316.5 98.8%  
Price / Book Value ratio x4.71.8 262.1%  
Dividend payout %6.428.9 22.0%   
Avg Mkt Cap Rs m444,390269,194 165.1%   
No. of employees `00014.04.0 348.4%   
Total wages/salary Rs m17,67817,939 98.5%   
Avg. sales/employee Rs Th10,667.821,190.3 50.3%   
Avg. wages/employee Rs Th1,264.34,470.1 28.3%   
Avg. net profit/employee Rs Th1,645.83,120.0 52.8%   
INCOME DATA
Net Sales Rs m149,15785,037 175.4%  
Other income Rs m1,1592,338 49.6%   
Total revenues Rs m150,31687,374 172.0%   
Gross profit Rs m34,34334,991 98.1%  
Depreciation Rs m4,2763,817 112.0%   
Interest Rs m66720,310 3.3%   
Profit before tax Rs m30,55813,202 231.5%   
Minority Interest Rs m501,699 3.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-100 0.0%   
Tax Rs m7,5972,281 333.0%   
Profit after tax Rs m23,01212,520 183.8%  
Gross profit margin %23.041.1 56.0%  
Effective tax rate %24.917.3 143.9%   
Net profit margin %15.414.7 104.8%  
BALANCE SHEET DATA
Current assets Rs m92,06287,590 105.1%   
Current liabilities Rs m66,223185,578 35.7%   
Net working cap to sales %17.3-115.2 -15.0%  
Current ratio x1.40.5 294.5%  
Inventory Days Days10631 341.4%  
Debtors Days Days6848 142.3%  
Net fixed assets Rs m62,919108,523 58.0%   
Share capital Rs m586345 169.8%   
"Free" reserves Rs m93,133148,481 62.7%   
Net worth Rs m93,719148,826 63.0%   
Long term debt Rs m1,814144,957 1.3%   
Total assets Rs m162,494482,394 33.7%  
Interest coverage x46.81.7 2,836.3%   
Debt to equity ratio x01.0 2.0%  
Sales to assets ratio x0.90.2 520.7%   
Return on assets %14.66.8 214.1%  
Return on equity %24.68.4 291.9%  
Return on capital %32.712.0 273.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m75,83815,001 505.6%   
Fx outflow Rs m30,2245,150 586.9%   
Net fx Rs m45,6139,851 463.0%   
CASH FLOW
From Operations Rs m32,786-100,393 -32.7%  
From Investments Rs m-17,870-24,202 73.8%  
From Financial Activity Rs m-19,153135,705 -14.1%  
Net Cashflow Rs m-4,23911,110 -38.2%  

Share Holding

Indian Promoters % 54.1 52.9 102.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 4.0 198.8%  
FIIs % 27.7 26.6 104.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 16.5 61.8%  
Shareholders   69,601 93,274 74.6%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   DIVIS LABORATORIES  WOCKHARDT LTD.  VENUS REMEDIES  PLETHICO PHARMA  GLENMARK PHARMA  

Compare AUROBINDO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Down Around 1%; Telecom & Metal Stocks Decline(01:30 pm)

Indian share markets are trading in the red presently. Sectoral indices are trading in the red with stocks in the telecom sector and metal sector witnessing maximum selling pressure.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Feb 19, 2018 03:37 PM

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA - FULFORD INDIA COMPARISON

COMPARE AUROBINDO PHARMA WITH

MARKET STATS